NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) will be presenting at the following conferences in September with webcasts available at Nasdaq’s Investor Relations website: https://ir.nasdaq.com/.

Who: Tal Cohen, President, Nasdaq
What: Autonomous 2026 Future of Commerce Symposium
When: Wednesday, September 23rd, 1:00 PM ET
   
Who: Sarah Youngwood, Executive Vice President & Chief Financial Officer, Nasdaq
What: Bank of America Securities 31st Annual Financials CEO Conference
When: Thursday, September 24th, 3:00 AM ET / 8:00 AM BST


About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the infrastructure of the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying advanced technology, data, and intelligence solutions that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at  www.nasdaq.com.

Media Relations Contact:
David Lurie
+1.914.538.0533
David.Lurie@Nasdaq.com

Investor Relations Contact:
Ato Garrett
+1.212.401.8737
Ato.Garrett@Nasdaq.com

-NDAQF-

SAXONBURG, Pa., Sept. 17, 2026 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: OHR), the global leader in photonics, today announced the expansion of its Pluggable Optical Line System (POLS) portfolio, with the full C-band, high-power variable-gain amplifier optical line system in a compact QSFP form factor. Designed for the latest generation of 800G ZR/ZR+ digital coherent optics, the enhanced POLS supports up to 32 DWDM wavelengths over a single fiber pair, enabling as much as 25.6Tbps of AI datacenter traffic across links from 2km to 200km.

Targeting the high-capacity interconnect requirements of Internet Service and Cloud Hosting Providers, and AI infrastructure operators, the enhanced POLS integrates key optical transport functions into QSFP modules that plug directly into standard transceiver slots. Thanks to Coherent’s high-performance miniature optical components, including dual-chip micropump lasers, POLS provides 21dBm output power, variable gain, low power consumption, and autonomous plug-and-play operation. Auto-provisioning manages link configuration and laser safety, while fixed wavelength and colorless MUX/DMUX options and asymmetric optical connectors simplify deployment and help prevent fiber-connection errors.

“As AI infrastructure scales, customers require optical connectivity that combines greater capacity, operational simplicity, and deployment flexibility,” said Madhu Krishnaswamy, Senior Vice President, Telecom Transport Business Unit at Coherent. “Since we first introduced POLS, Coherent has continued to advance the ultra-compact optical components that enable this platform, including our dual-chip 700mW uncooled 3-pin 980nm pump laser and isolator-tap photodiode technology. By extending plug-and-play operation across the full C-band, we are helping customers reduce the traditional tradeoffs between performance and operational simplicity. This advancement represents another important step toward more automated, open, and high-capacity optical networks for the AI era.”

The enhanced POLS is generally available and shipped in high volume. Coherent offers versions supporting 400G and 800G ZR and ZR+ applications with either SFF-8636 or CMIS 4.0 memory maps, enabling straightforward deployment in existing network environments.

Visitors to ECOC 2026 are invited to experience the latest POLS technology at the Coherent Booth #2100. Additional product information is available at www.coherent.com.

About Coherent 

Coherent is the global photonics leader. We harness photons to drive innovation. Industry leaders in the datacenter, communications, and industrial markets rely on Coherent’s world-leading technology to fuel their own innovation and growth.

Founded in 1971 and operating in more than 20 countries, Coherent brings the industry’s broadest, deepest technology stack; unmatched supply chain resilience; and global scale to help its customers solve their toughest technology challenges. For more information, visit us at coherent.com.

Media Contact:
innovations@coherent.com 

BOSTON, Sept. 17, 2026 (GLOBE NEWSWIRE) — Rapid7, Inc. (“Rapid7”) (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, announced that the company granted inducement awards, effective as of September 15, 2026, to employees as a material inducement to commence employment with Rapid7 and its subsidiaries.

We granted inducement awards comprised of 290,626 restricted stock units (“RSUs”) in respect of Rapid7’s common stock, in the aggregate, to 3 employees.

The RSUs vest over a three-year period with one-third (1/3) of the RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining two-thirds (2/3) of the RSUs vesting in equal quarterly installments thereafter through the third anniversary of the vesting commencement date, subject to continued employment through each applicable vesting date.

The RSUs were granted under Rapid7’s 2015 Equity Incentive Plan, as amended (the “Equity Plan”) pursuant to the Equity Plan’s inducement award share pool. The RSUs were unanimously approved by Rapid7’s Compensation Committee, which is independent within the meaning of Nasdaq Listing Rule 5605(a)(2), in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for the employees to commence employment with Rapid7.

About Rapid7

Rapid7, Inc. (NASDAQ: RPD) is a global leader in AI-powered managed cybersecurity operations, trusted to advance organizations’ cyber resilience. Open and extensible, the Rapid7 Command Platform integrates security data, enriching it with AI, threat intelligence, and 25 years of expertise and innovation to reduce risk and disrupt attackers. As a recognized leader in preemptive managed detection and response (MDR), Rapid7 unifies exposure and detection to transform the cybersecurity operations of more than 11,500 customers worldwide. For more information, visit our website, check out our blog, or follow us on LinkedIn or X.

Rapid7 Press Contact
Christine Nurnberger
SVP Global Marketing and Growth 
press@rapid7.com

Rapid7 Investor Contact
Ryan Flanagan and Ryan Gardella
ICR for Rapid7
investors@rapid7.com
(617) 865-4277

Source: Rapid7

GLYFADA, Greece, Sept. 17, 2026 (GLOBE NEWSWIRE) — Globus Maritime Limited (“Globus” or the “Company”), (NASDAQ: GLBS), a dry bulk shipping company, announced the results of its annual meeting of shareholders, held earlier today in Glyfada, Greece. The following proposals were approved and adopted at the meeting:

  1. the election of Mr. Athanasios “Thanos” Feidakis and Mr. Ioannis Kazantzidis as Class I directors of the Company, to serve until the 2029 Annual Meeting of Shareholders; and
  2. the appointment of Ernst & Young (Hellas) Certified Auditors Accountants S.A., as the Company’s independent auditors for the fiscal year ending December 31, 2026.

About Globus Maritime Limited

Globus is an integrated dry bulk shipping company that provides marine transportation services worldwide and presently owns, operates and manages a fleet of ten dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina and other dry bulk cargoes internationally. Globus’ subsidiaries own and operate ten vessels with a total carrying capacity of approximately 744,622DWT and a weighted average age of about 8 years as of September 17, 2026.

Safe Harbor Statement

This communication contains “forward-looking statements” as defined under U.S. federal securities laws. Forward-looking statements provide the Company’s current expectations or forecasts of future events. Forward-looking statements include statements about the Company’s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts or that are not present facts or conditions. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The Company’s actual results could differ materially from those anticipated in forward-looking statements for many reasons specifically as described in the Company’s filings with the Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements, which speak only as of the date of this communication. Globus undertakes no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this communication or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks Globus describes in the reports it files from time to time with the Securities and Exchange Commission.

   
For further information please contact:
   
Globus Maritime Limited +30 210 960 8300
Athanasios Feidakis, CEO a.g.feidakis@globusmaritime.gr
   
Capital Link – New York +1 212 661 7566
Nicolas Bornozis globus@capitallink.com
   

Satellite completes next-generation constellation, increasing service capability in key markets

ViaSat-3 F2 Satellite

The ViaSat-3 F2 satellite has entered service across the Americas, significantly expanding the company's network capacity, flexibility and resilience across the region.
The ViaSat-3 F2 satellite has entered service across the Americas, significantly expanding the company’s network capacity, flexibility and resilience across the region.

CARLSBAD, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — Viasat, Inc. (NASDAQ: VSAT), a global leader in satellite communications technology, today announced that its ViaSat-3 (VS3) F2 satellite has entered service across the Americas, significantly expanding the company’s network capacity, flexibility and resilience across the region. The satellite strengthens Viasat’s ability to deliver advanced connectivity services while creating new opportunities for growth in key markets and enhancing network economics.

“With the VS3 constellation now fully operational, we have substantially expanded our ability to deliver high-quality connectivity where demand is growing fastest and introduced new forms of resilience for our government and commercial customers,” said Mark Dankberg, Chairman and CEO of Viasat. “This is a major milestone for Viasat and our customers and positions us well to deliver differentiated experiences and support our highest-value markets around the world.”

Dankberg continued, “We believe that the VS3 satellites are the most advanced commercial satellites in the world in terms of adaptive beam forming for cost efficiencies, user performance improvements that offer higher speeds on both forward and return links, and resilience to interference. We also believe VS3 technology sets new commercial standards for solar power generation and thermal dissipation — both critical technology challenges for developing economical data centers in space.”

ViaSat-3 F2 is designed to provide more than one terabit per second of throughput capacity over the Americas, significantly increasing the company’s ability to meet growing demand for reliable connectivity in the air, at sea and on the ground. The satellite’s advanced beamforming technology dynamically allocates capacity to high-demand flight routes, shipping lanes and geographic regions, helping maximize network performance where demand and opportunity are greatest and improve customer experience where it matters most.

With ViaSat-3 F1 already in service and F3 entering service across Asia-Pacific in August, completion of the ViaSat-3 constellation has tripled the bandwidth available across Viasat’s global fleet, providing the scale, flexibility and reach needed to better support the company’s aviation, maritime, government, and broadband customers and establishing a powerful foundation for continued growth.

About Viasat
Viasat is a global technology company that believes everyone and everything in the world can be connected. With offices in 24 countries around the world, our mission shapes how consumers, businesses, governments and militaries around the world communicate and connect. Viasat is developing the ultimate global communications network to power high-quality, reliable, secure, affordable, fast connections to positively impact people’s lives anywhere they are — on the ground, in the air or at sea — while building a sustainable future in space. In May 2023, Viasat completed its acquisition of Inmarsat, combining the teams, technologies and resources of the two companies to create a new global communications partner. Learn more at www.viasat.com, the Viasat News Room or follow us on LinkedIn, X, Instagram, Facebook, Bluesky, Threads, and YouTube.

Copyright © 2026 Viasat, Inc. All rights reserved. Viasat, the Viasat logo and the Viasat Signal are registered in the U.S and in other countries to Viasat, Inc. All other product or company names mentioned are used for identification purposes only and may be trademarks of their respective owners.

Viasat, Inc. Contacts
Scott Goryl / Daniel Bleier, Corporate Communications, PR@viasat.com
Lisa Curran / Peter Lopez, Investor Relations, IR@viasat.com

Forward-Looking Statements
This press release contains forward-looking statements that are subject to the safe harbors created under the Securities Act of 1933 and the Securities Exchange Act of 1934. Forward-looking statements include, among others, statements related to the performance, capabilities and anticipated benefits of the ViaSat-3 satellite platform, including expected capacity, coverage and flexibility. Readers are cautioned that actual results could differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause actual results to differ include: risks associated with operation of the ViaSat-3 class satellites, including the effect of any anomaly, operational failure or degradation in satellite performance; the ability to realize the anticipated benefits of the ViaSat-3 satellite platforms; unexpected expenses or delays related to the satellite system; the ability to successfully implement Viasat’s business plan for broadband satellite services on Viasat’s anticipated timeline or at all, including with respect to the ViaSat-3 satellite platform; contractual problems, product defects, manufacturing issues or delays; regulatory issues; technologies not being developed according to anticipated schedules, or that do not perform according to expectations; and increased competition and other factors affecting the connectivity sector, generally. In addition, please refer to the risk factors contained in Viasat’s SEC filings available at www.sec.gov, including Viasat’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. Viasat undertakes no obligation to update or revise any forward-looking statements for any reason.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e1d4be7b-7205-4012-8bc5-90cb6d6b8e40

IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per share, which equals the public offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. In addition, the underwriters exercised their option in full and purchased 1,304,348 additional shares of common stock. Including the option exercise, the aggregate gross proceeds from this offering were $172.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Beta Bionics.

Beta Bionics expects to use the net proceeds from this offering for general corporate purposes, which may include costs associated with the commercialization of Mint™, including expansion of Beta Bionics’ manufacturing facilities, research and development and clinical development, investment in product enhancements, potential strategic opportunities and working capital and operating expenses.

J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners acted as the joint book-running managers for the offering.

The shares of common stock and pre-funded warrants described above were offered by Beta Bionics pursuant to a shelf registration statement on Form S-3 that was filed by Beta Bionics with the Securities and Exchange Commission (SEC) on February 24, 2026 and automatically became effective upon filing. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or from Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com; or from Wells Fargo Securities, LLC, Attention: Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, by telephone at 800-645-3751 (option #5), by email at WFScustomerservice@wellsfargo.com; or from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD.

Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as “may,” “expects,” “goal,” “intend,” “will,” “would,” “subject to” or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding Beta Bionics’ expectations with respect to the use of proceeds from the offering. For such statements, Beta Bionics claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Beta Bionics’ expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, those factors disclosed in Beta Bionics’ filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as updated by its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 29, 2026, and other filings that Beta Bionics may make from time to time with the SEC. These forward-looking statements represent Beta Bionics’ judgment as of the time of this release. Beta Bionics disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com

Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com

MINNEAPOLIS, Sept. 17, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) (“Vireo” or the “Company”), a leading cannabis company and agricultural markets platform today announced that, in connection with a confidential settlement agreement (the “Settlement Agreement”) with SHWZ Altmore, LLC (“Altmore”) and certain other parties, the Company will issue a total of 462,963 subordinate voting shares of the Company (the “Settlement Shares”) to Altmore and Altmore Debt I, LP as consideration for the Company’s acquisition of certain secured obligations and related liens held by Altmore (the “Assigned Interest”), pursuant to an assignment and assumption agreement entered into in connection with the Settlement Agreement.

The Settlement Shares will be subject to a six (6) month lock-up period commencing on the date of issuance and applicable resale restrictions, during which the holders may not transfer the Settlement Shares without the Company’s prior written consent. The additional terms of the Settlement Agreement remain confidential.

About Vireo Growth Inc.

Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) is a leading vertically integrated cannabis company building a broad platform across cannabis and adjacent agricultural markets. The Company operates cultivation, manufacturing, retail dispensaries, home delivery, distribution, and agricultural supply businesses across the United States, creating exposure to both cannabis and complementary adjacent markets. With operations in 10 states and approximately 170 dispensaries nationwide, Vireo combines disciplined capital allocation, strategic acquisitions, and local market execution to scale its platform and drive long-term shareholder value. The Company is focused on expanding market share and strengthening its portfolio of consumer brands and services, while supporting the customers, employees, shareholders, and communities it serves. For more information about Vireo, visit www.vireogrowth.com.

Forward-Looking Statement Disclosure

This press release contains “forward-looking statements” or “forward-looking information” within the meaning of applicable United States and Canadian securities legislation (collectively, “forward-looking information”). To the extent any forward-looking information in this press release constitutes “financial outlooks” within the meaning of applicable United States or Canadian securities laws, this information is being provided as preliminary financial results; the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks.

Forward-looking information contained in this press release may be identified by the use of words such as “intend,” “anticipate,” “plan,” “project,” “potential,” “could,” “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” and variations of such words and phrases, or any statements or clauses containing verbs in any future tense and includes, but is not limited to expectations around the issuance of the Settlement Shares and the acquisition of the Assigned Interest. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or the Company’s subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although Vireo believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because Vireo cannot give any assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks and uncertainties associated with the Assigned Interest acquired by the Company; risks related to the timing and content of adult-use legislation in markets where Vireo currently operates; current and future market conditions, including the market price of the Company’s subordinate voting shares; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to meet the demand for flower in its various markets; and risk factors set out in Vireo’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under each company’s profile on SEDAR+ at www.sedarplus.ca.

The statements in this press release are made as of the date of this release. Except as required by law, Vireo will not undertake any obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.

Contact Information

Vireo Growth Inc.
Lynn Ricci
Director, Investor Relations & Corporate Communications
investor@vireogrowth.com
(781) 956-7052

Technology Partnership Targets a Potential Step-Change in Refrigerant Recovery and Separation Efficiency

WOODCLIFF LAKE, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) announced it has signed a joint development agreement with Icorium Company for the commercialization of Icorium’s patented extractive distillation technology.

The collaboration is expected to broaden and complement Hudson’s existing fractional distillation systems with the potential for rapid and more complete processing of more complex refrigerant compositions through Icorium’s single-stream extractive method. The technology under development pursues the ability to split complicated refrigerant mixtures into their core components – including azeotropes – with a yield and throughput previously unknown in the industry. The ability to separate and purify traditionally difficult refrigerant blends will simplify recovery of used refrigerants by allowing contractors to combine refrigerants in cylinders, reducing onsite recovery time and also enabling Hudson to extract the maximum refrigerant possible from every pound of refrigerant recovered, thereby producing a faster transition from stock to saleable product.

The joint development agreement provides Hudson with dedicated access to Icorium’s engineering resources, access to Icorium intellectual property related to refrigerant separation technologies, exclusivity and first-mover advantages during the initial commercialization period, as well as early access to additional separation technologies which may create further opportunities for expansion into new markets.

Ken Gaglione, President and Chief Executive Officer of Hudson Technologies commented, “This agreement marks a significant milestone for us as we execute our strategy to expand our offerings beyond traditional refrigerant sales and reclamation to include a premier technology-driven platform for recovery, purification, and separation services. With Icorium’s technology, we seek to separate complex refrigerant blends with greater speed and efficiency than traditional fractional distillation, substantially enhancing our capabilities and capacity. The ability to convert a broader range of refrigerants into saleable product would create a differentiated competitive advantage for Hudson as our industry moves from conventional to next-generation equipment and refrigerants.”

“We are excited to work with Hudson to scale our patented distillation technology to broaden and support the practice of refrigerant recovery and reclamation. Hudson and Icorium share a commitment to promoting and facilitating responsible refrigerant management. The combination of Hudson’s scale and market reach with our technology may open meaningful commercialization pathways in the continued development of a circular refrigerant supply chain,” commented Dr. Kalin Baca, co-Founder and CEO of Icorium.

About Hudson Technologies         

Hudson Technologies, Inc. is a leading provider of innovative and sustainable refrigerant products and services to the Heating Ventilation Air Conditioning and Refrigeration industry. For nearly three decades, we have demonstrated our commitment to our customers and the environment by becoming one of the first in the United States and largest refrigerant reclaimers through multimillion dollar investments in the plants and advanced separation technology required to recover a wide variety of refrigerants and restoring them to Air-Conditioning, Heating, and Refrigeration Institute standard for reuse as certified EMERALD Refrigerants™. The Company’s products and services are primarily used in commercial air conditioning, industrial processing and refrigeration systems, and include refrigerant and industrial gas sales, refrigerant management services consisting primarily of reclamation of refrigerants and RefrigerantSide® Services performed at a customer’s site, consisting of system decontamination to remove moisture, oils and other contaminants for data centers and a wide range of other industrial applications. As a component of the Company’s products and services, the Company also generates carbon offset projects.

About Icorium

Icorium is an advanced separation technology company redefining refrigerant reclamation. Its proprietary separation technology, built on ionic liquid-based extractive distillation, hollow fiber membranes and pressure swing adsorption using porous materials, recovers high-purity refrigerants from complex mixtures that would otherwise be stockpiled, destroyed or released into the atmosphere. This scalable platform helps the industry meet evolving environmental regulations, reduce waste and advance toward a circular refrigerant economy. Founded in 2022 as a University of Kansas spinout, Icorium is headquartered at KU Innovation Park in Lawrence, Kan., and has earned national recognition for its innovation, including National Science Foundation funding and multiple startup awards. Learn more at icorium.us.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained herein which are not historical facts constitute forward-looking statements. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such factors include, but are not limited to, changes in the laws and regulations affecting the industry, changes in the demand and price for refrigerants (including unfavorable market conditions adversely affecting the demand for, and the price of, refrigerants), the Company’s ability to source refrigerants, regulatory and economic factors, seasonality, competition, litigation, the nature of supplier or customer arrangements that become available to the Company in the future, adverse weather conditions, possible technological obsolescence of existing products and services, possible reduction in the carrying value of long-lived assets, estimates of the useful life of its assets, potential environmental liability, customer concentration, the ability to obtain financing, the ability to meet financial covenants under its existing credit facility, any delays or interruptions in bringing products and services to market, the timely availability of any requisite permits and authorizations from governmental entities and third parties as well as factors relating to doing business outside the United States, including changes in the laws, regulations, policies, and political, financial and economic conditions, including inflation, interest and currency exchange rates, of countries in which the Company may seek to conduct business, the Company’s ability to successfully integrate any assets it acquires from third parties into its operations, and other risks detailed in the Company’s 10-K for the year ended December 31, 2025 and other subsequent filings with the Securities and Exchange Commission. The words “believe”, “expect”, “anticipate”, “may”, “plan”, “should” and similar expressions identify forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.

Investor Relations Contact:
John Nesbett/Jennifer Belodeau
IMS Investor Relations
(203) 972-9200
jnesbett@imsinvestorrelations.com
Company Contact:
Brian Bertaux, CFO
Hudson Technologies, Inc.
(845) 735-6000
bbertaux@hudsontech.com

WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 14 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 278,100 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on September 15, 2026, and restricted stock units with respect to an aggregate of 88,400 shares of Dyne’s common stock. The stock options have a ten-year term and are scheduled to vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee’s continued service to Dyne through the applicable vesting dates. The restricted stock units are scheduled to vest over four years from the applicable employee’s start date in four equal annual installments, subject to such employee’s continued service to Dyne through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938

September 17, 2026 – 22:01PM CET

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of Shareholders and appointments of Thomas M. Brakel and Khurem Farooq as non-executive directors of the Company’s Board of Directors.

“We welcome Tom and Khurem to the Board and look forward to learning from their combined years of leadership and expertise. Our focus at argenx today remains as ever before, on our scientific innovation mission, delivering value for shareholders, and always deepening the impact we make for patients and their communities. As we look ahead to Vision 2030 and beyond, we are building a company, and a board, with the strength and perspective to sustain and grow what argenx contributes to patients, science, and society for decades to come,” said Tim Van Hauwermeiren, Chairperson of the Board of argenx.

The voting result and all documents relating to the shareholders’ meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.

About argenx 
argenx is the global immunology innovation company committed to improving the lives of people suffering from diseases with high unmet need. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  www.argenx.com  and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts
Media:
Ben Petok
bpetok@argenx.com

Investors:
Alexandra Roy  
aroy@argenx.com 

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.